FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 345 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR UK health inequalities: 20,000 more cancer cases a year in the... September 29, 2020 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... September 2, 2025 Researchers Believe Antibodies from Alpacas Could Be Key to Curing Cancer,... August 15, 2019 Clinical Benefit of Pembrolizumab in Patients with Previously Treated Advanced Clear... March 4, 2025 Load more HOT NEWS Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t... Adjuvant Pembrolizumab Continues to Demonstrate a Clinically Meaningful DMFS Benefit in... Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive...
